Cleo S. M. Funk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cleo S. M. Funk has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Schmidt
Department of Psychology, Humboldt-Universität zu Berlin, Berlin, Germany
1 shared publication - Engi Abdelhady Algharably
Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany
1 shared publication - Eva Janina Brandl
Psychiatrische Universitätsklinik der Charité im St. Hedwig-Krankenhaus, Charité – Universitätsmedizin Berlin
1 shared publication - Felix Bermpohl
Department of Psychiatry and Neuroscience, Charité Campus Mitte, Charité—University Medicine Berlin, 10117 Berlin, Germany
1 shared publication - Nadine Bittner
Department of Psychiatry and Psychotherapy, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
1 shared publication - Reinhold Kreutz
Institute of Clinical Pharmacology and Toxicology, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité-Universitätsmedizin Berlin , Berlin
1 shared publication
Latest Publications
- Open Access
- 8 September 2023
- Published by Springer Nature in Drugs & Aging
- Vol. 40 (11) , 953-964
Psychiatric Adverse Events of Acetylcholinesterase Inhibitors in Alzheimer’s Disease and Parkinson’s Dementia: Systematic Review and Meta-Analysis
Background The acetylcholinesterase inhibitors (AChEIs) donepezil, galantamine, and rivastigmine are commonly used in the management of various forms of dementia. Objectives While these drugs are known to induce classic cholinergic adverse events such as diarrhea, their potential to cause psychiatric adverse events has yet to be thoroughly examined. Methods We sought to determine the risk of psychiatric adverse events associated with the use of AChEIs through a systematic review and meta-analysis of double-blind randomized controlled trials involving patients with Alzheimer’s dementia and Parkinson’s dementia. Results A total of 48 trials encompassing 22,845 patients were included in our analysis. Anorexia was the most commonly reported psychiatric adverse event, followed by agitation, insomnia, and depression. Individuals exposed to AChEIs had a greater risk of experiencing appetite disorders, insomnia, or depression compared with those who received placebo (anorexia: odds ratio [OR] 2.93, 95% confidence interval [CI] 2.29–3.75; p < 0.00001; decreased appetite: OR 1.93, 95% CI 1.33–2.82; p = 0.0006; insomnia: OR 1.55, 95% CI 1.25–1.93; p < 0.0001; and depression: OR 1.59, 95% CI 1.23–2.06, p = 0.0004). Appetite disorders were also more frequent with high-dose versus low-dose therapy. A subgroup analysis revealed that the risk of insomnia was higher for donepezil than for galantamine. Conclusions Our findings suggest that AChEI therapy may negatively impact psychological health, and careful monitoring of new psychiatric symptoms is warranted. Lowering the dose may resolve some psychiatric adverse events, as may switching to galantamine in the case of insomnia. Clinical Trial Registration The study was pre-registered on PROSPERO (CRD42021258376).
- 8 September 2023
- Published by Springer Nature in Drugs & Aging
- Vol. 40 (11) , 953-964
Open AccessPsychiatric Adverse Events of Acetylcholinesterase Inhibitors in Alzheimer’s Disease and Parkinson’s Dementia: Systematic Review and Meta-Analysis
Background The acetylcholinesterase inhibitors (AChEIs) donepezil, galantamine, and rivastigmine are commonly used in the management of various forms of dementia. Objectives While these drugs are known to induce classic cholinergic adverse events such as diarrhea, their potential to cause psychiatric adverse events has yet to be thoroughly examined. Methods We sought to determine the risk of psychiatric adverse events associated with the use of AChEIs through a systematic review and meta-analysis of double-blind randomized controlled trials involving patients with Alzheimer’s dementia and Parkinson’s dementia. Results A total of 48 trials encompassing 22,845 patients were included in our analysis. Anorexia was the most commonly reported psychiatric adverse event, followed by agitation, insomnia, and depression. Individuals exposed to AChEIs had a greater risk of experiencing appetite disorders, insomnia, or depression compared with those who received placebo (anorexia: odds ratio [OR] 2.93, 95% confidence interval [CI] 2.29–3.75; p < 0.00001; decreased appetite: OR 1.93, 95% CI 1.33–2.82; p = 0.0006; insomnia: OR 1.55, 95% CI 1.25–1.93; p < 0.0001; and depression: OR 1.59, 95% CI 1.23–2.06, p = 0.0004). Appetite disorders were also more frequent with high-dose versus low-dose therapy. A subgroup analysis revealed that the risk of insomnia was higher for donepezil than for galantamine. Conclusions Our findings suggest that AChEI therapy may negatively impact psychological health, and careful monitoring of new psychiatric symptoms is warranted. Lowering the dose may resolve some psychiatric adverse events, as may switching to galantamine in the case of insomnia. Clinical Trial Registration The study was pre-registered on PROSPERO (CRD42021258376).